Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database

Home Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database

Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database

A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer

/ Publications

Share the Post

About the Author

Related Posts

PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Read More
Richard Maroun, JD
UPDATE — Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
Aadi Bioscience Closes $23 Million in Series A Funding

Comments

Comments are closed.